# Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

> **NCT02389933** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Heart Failure With Reduced Ejection Fraction (HF-rEF)

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT02389933
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389933, "Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02389933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*